

Spatial Genomics & Transcriptomics Market by Product (Instruments, Consumables, Services), Technique (Transcriptomics (IHC, ISH), Genomics (LCM), Service Type (Sample Prep, Sequencing), Application (Translation Research (Cancer)) - Global Forecast to 2029

<https://marketpublishers.com/r/SE6D93297642EN.html>

Date: January 2025

Pages: 450

Price: US\$ 4,950.00 (Single User License)

ID: SE6D93297642EN

Abstracts

The spatial genomics & transcriptomics product market is expected to reach USD 995.7 million in 2029 from USD 554.5 million in 2024, at a CAGR of 12.4% during the forecast period.

The spatial genomics and transcriptomics market is expanding under the influence of factors like new product introduction and rising acceptance of spatial genomics and transcriptomics in medication discovery and development. Nevertheless, expensive initial capital inputs and technical complexity and knowledge gap create various difficulties for the industry.

'The product segment accounted for the largest share by offering segment in the spatial genomics & transcriptomics market in 2023'.

Products and services divide the spatial genomics & transcriptomics market. In 2023 the product segment held the biggest share. The growing demand for high-resolution spatial gene and protein expression data in research helps to explain the expansion of this area. The main forces behind the market expansion are the expanding uses of consumables and spatial genomics and transcriptomics in drug research and development as well as biomarker identification. Key element driving development in this market segment is increased investments by market participants in creating various

software especially for spatial analysis and introduction of new goods.

'The spatial transcriptomics technique held the highest market share of the spatial genomics and transcriptomics market by technique in 2023'.

Techniques divide the spatial genomics and transcriptomics market into spatial transcriptomics and spatial genomics segments. Driven by growing acceptance of in situ sequencing technologies and more general applications in disease research, the segment of spatial transcriptomics held the biggest share of spatial genomics & transcriptomics market in 2023. Using spatial transcriptomics, one may map gene expression inside the spatial context of a tissue. Combining histology and molecular data reveals how genes are expressed in certain tissue country or region, so providing understanding of cellular organization, function, and disease progression.

'The Asia Pacific region is growing at the highest CAGR in the spatial genomics & transcriptomics market from 2024 to 2029.'

The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a

increasing government efforts to rising healthcare needs, growing government investment in

biotechnology, growing demand of precision medicine, rising healthcare expenditure, growing

R&D expansion in key markets such as India, China, and Japan, and the favorable regulatory

environment in the region. However, North America held the largest share of spatial genomics & transcriptomics market in 2023.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 60% and Demand Side 40%

By Designation: Managers - 45% CXOs and Director-level - 30%, and

Executives - 25%,

By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

NanoString Technologies, Inc. (Bruker Spatial Biology, Inc.) (US)

10x Genomics (US)

Bio-Rad Laboratories, Inc. (US)

Illumina, Inc. (US)

Bio-Techne (US)

Seven Bridges Genomics (US)

Rarecyte, Inc. (US)

Standard BioTools (US)

Revvity (US)

Akoya Biosciences, Inc. (US)

Natera, Inc. (US)

VisioPharm A/S (Switzerland)

Danaher Corporation (US)

Veracyte, Inc. (US)

Biomarker Technologies (BMKGENE) (China)

Macrogen, Inc. (South Korea)

Miltenyi Biotec (Germany)

Sony Biotechnology Inc. (US)

Vizgen Inc. (US)

BioSpyder, Inc. (US)

Ionpath, Inc. (US)

S2 Genomics, Inc. (US)

Ultivue, Inc. (US)

Admera Health (US)

Lunaphore Technologies SA (US)

Visikol, Inc. (US)

Rebus Biosystems, Inc. (US)

Singular Genomics Systems, Inc. (US)

Cantata Bio (US)

Nucleai, Inc. (Israel)

Research Coverage:

This research report categorizes the spatial genomics & transcriptomics market by offering (products and services), by technique (spatial transcriptomics and spatial genomics), by type (service) (sample preparation services, sequencing & analytical services, and data visualization & analysis services), by application (translational research and drug discovery & development), by end user (product) (pharmaceutical &

biotechnology companies, academic & research institutes, CROs & CDMOs, and clinical diagnostic laboratories), by end user (service) (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the spatial genomics & transcriptomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the spatial genomics & transcriptomics market. Competitive analysis of top players and upcoming startups in the spatial genomics & transcriptomics market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall spatial genomics & transcriptomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing adoption of spatial genomics and transcriptomics in drug discovery and development, Introduction of novel products, Increasing pharmaceutical R&D investments and public-private funding), restraints (High initial capital investments and maintenance costs, Technical complexity and expertise gap), opportunities (Increasing use of spatial omics for biomarker identification, Increasing demand for precision medicines and targeted drug development), and challenges (Dearth of skilled professionals) influencing the growth of the market.

Product Development/Innovation: Detailed insights on newly launched product/services of the spatial genomics & transcriptomics market

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the spatial genomics & transcriptomics market

Competitive Assessment: NanoString Technologies, Inc. (Bruker Spatial Biology, Inc.) (US), 10x Genomics (US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Bio-Techne (US), Seven Bridges Genomics (US), Rarecyte, Inc. (US), Standard BioTools (US), Revvity (US), Akoya Biosciences, Inc. (US), Natera, Inc. (US), VisioPharm A/S (Switzerland), Danaher Corporation (US), Veracyte, Inc. (US), Biomarker Technologies (BMKGENE) (China), MacroGen, Inc. (South Korea), Miltenyi Biotec (Germany), Sony Biotechnology Inc. (US), Vizgen Inc. (US), BioSpyder, Inc. (US), Ionpath, Inc. (US), S2 Genomics, Inc. (US), Ultivue, Inc. (US), Admera Health (US), Lunaphore Technologies SA (US), Visikol, Inc. (US), Rebus Biosystems, Inc. (US), Singular Genomics Systems, Inc. (US), Cantata Bio (US), and Nucleai, Inc. (Israel).

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 INCLUSIONS & EXCLUSIONS
- 1.4 STUDY SCOPE
 - 1.4.1 SEGMENTS AND REGIONS CONSIDERED
 - 1.4.2 YEARS CONSIDERED
 - 1.4.3 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
 - 1.6.1 IMPACT OF AI/GEN AI

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Objectives of secondary research
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Breakdown of primaries
 - 2.1.2.2 Objectives of primary research
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
 - 2.2.1.1 Insights from primary sources
 - 2.2.2 SEGMENTAL MARKET ESTIMATION: TOP-DOWN APPROACH (PRODUCT)
- 2.3 GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET OVERVIEW
- 4.2 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS

MARKET SHARE, BY TECHNIQUE AND COUNTRY (2023)

4.3 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET:
GEOGRAPHIC GROWTH OPPORTUNITIES

4.4 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET SHARE,
BY END USER (2023)

4.5 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET SHARE,
BY END USER (2023)

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Increasing adoption of spatial genomics and transcriptomics in drug discovery and development

5.2.1.2 Introduction of novel products

5.2.1.3 Increasing pharmaceutical R&D investments and public-private funding

5.2.2 RESTRAINTS

5.2.2.1 High initial capital investments and maintenance costs

5.2.2.2 Technical complexity and expertise gap

5.2.3 OPPORTUNITIES

5.2.3.1 Increasing use of spatial omics for biomarker identification

5.2.3.2 Growing demand for precision medicines and targeted drug development

5.2.4 CHALLENGES

5.2.4.1 Dearth of skilled professionals

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

5.4 PRICING ANALYSIS

5.4.1 AVERAGE SELLING PRICE TREND OF INSTRUMENTS,
BY KEY PLAYER, 2021–2023

5.4.2 AVERAGE SELLING PRICE TREND OF CONSUMABLES,
BY KEY PLAYER, 2021–2023

5.4.3 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION, 2021–2023

5.5 SUPPLY CHAIN ANALYSIS

5.6 VALUE CHAIN ANALYSIS

5.7 ECOSYSTEM ANALYSIS

5.8 TECHNOLOGY ANALYSIS

5.8.1 KEY TECHNOLOGIES

5.8.1.1 In-situ sequencing

5.8.1.2 In-situ hybridization

- 5.8.1.3 Single-cell RNA sequencing
- 5.8.2 COMPLEMENTARY TECHNOLOGIES
 - 5.8.2.1 Multi-isotope imaging mass spectrometry
 - 5.8.2.2 Spatial heatmap
 - 5.8.2.3 Differential gene expression analysis
- 5.8.3 ADJACENT TECHNOLOGIES
 - 5.8.3.1 Multi-omics
 - 5.8.3.2 Metabolomics
 - 5.8.3.3 Single-cell analysis
- 5.9 PATENT ANALYSIS
- 5.10 KEY CONFERENCES & EVENTS, 2025–2026
- 5.11 REGULATORY LANDSCAPE
 - 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 - 5.11.2 REGULATORY FRAMEWORK
- 5.12 PORTER'S FIVE FORCES ANALYSIS
 - 5.12.1 THREAT OF NEW ENTRANTS
 - 5.12.2 THREAT OF SUBSTITUTES
 - 5.12.3 BARGAINING POWER OF BUYERS
 - 5.12.4 BARGAINING POWER OF SUPPLIERS
 - 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
 - 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
 - 5.13.2 KEY BUYING CRITERIA, BY END USER (PRODUCT)
- 5.14 TRADE ANALYSIS
 - 5.14.1 IMPORT DATA FOR HS CODE 902790
 - 5.14.2 EXPORT DATA FOR HS CODE 902790
- 5.15 INVESTMENT & FUNDING SCENARIO
- 5.16 IMPACT OF AI/GEN AI ON SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET

6 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY OFFERING

- 6.1 INTRODUCTION
- 6.2 PRODUCTS
 - 6.2.1 INSTRUMENTS & SOFTWARE
 - 6.2.1.1 Instruments & software to facilitate disease research by enabling detailed spatial mapping and multi-omic analyses
 - 6.2.2 CONSUMABLES

6.2.2.1 Better reproducible and high-quality data collection to advance spatial genomics research in oncology and precision medicine

6.3 SERVICES

6.3.1 INCREASING DEMAND FOR HIGH-QUALITY SPATIAL DATA IN PRECISION MEDICINE TO AUGMENT MARKET GROWTH

7 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,

BY TECHNIQUE

7.1 INTRODUCTION

7.2 SPATIAL TRANSCRIPTOMICS

7.2.1 IMMUNOHISTOCHEMISTRY

7.2.1.1 Increasing applications in biomarker discovery and cellular interactions within tissue architecture to drive segment

7.2.2 IMMUNOFLUORESCENCE

7.2.2.1 Advanced profiling immune-tumor microenvironments for cancer diagnosis and prognosis to propel segment growth

7.2.3 MICROSCOPY-BASED RNA IMAGING

7.2.3.1 Better insights into molecular communication within tissue architecture to augment segment growth

7.2.4 IN-SITU HYBRIDIZATION

7.2.4.1 High-throughput and 3D spatial gene expression analysis in cancer research and developmental biology to drive segment

7.2.5 LASER CAPTURE MICRODISSECTION

7.2.5.1 Analysis of gene expression data from defined cellular populations to facilitate spatial mapping within tissue sections

7.2.6 RNA SEQUENCING

7.2.6.1 In-situ RNA sequencing

7.2.6.1.1 Integration of ISS with bioinformatics toolkits for data analysis to facilitate interpretation of complex datasets

7.2.6.2 Single-cell RNA (SC-RNA) sequencing

7.2.6.2.1 Increasing commercial availability of scRNA-seq platforms and advancements in bioinformatics tools to drive segment

7.2.6.3 Other RNA sequencing

7.2.7 OTHER SPATIAL TRANSCRIPTOMIC TECHNIQUES

7.3 SPATIAL GENOMICS

7.3.1 IN-SITU HYBRIDIZATION

7.3.1.1 Demand for high-specificity detection platforms to fuel market growth

7.3.2 LASER CAPTURE MICRODISSECTION

7.3.2.1 Detailed insights into cellular mechanisms and molecular profiles within heterogeneous tissue samples to drive segment

7.3.3 GENOMIC SEQUENCING

7.3.3.1 Microdissection-based sequencing

7.3.3.1.1 Increased demand for precision medicines to boost segment growth

7.3.3.2 Chromatin accessibility sequencing

7.3.3.2.1 Need for insights into gene regulation and epigenetic modifications to aid segment growth

7.3.3.3 Other genomic sequencing

7.3.4 OTHER SPATIAL GENOMIC TECHNIQUES

8 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY TYPE

8.1 INTRODUCTION

8.2 SAMPLE PREPARATION SERVICES

8.2.1 NEED FOR ACCURATE SPATIAL ANALYSIS OF GENE EXPRESSION WITHIN TISSUE SAMPLES TO SPUR MARKET GROWTH

8.3 SEQUENCING & ANALYTICAL SERVICES

8.3.1 SEQUENCING & ANALYTICAL SERVICES TO UTILIZE ADVANCED TECHNOLOGIES FOR SEQUENCING AND BIOINFORMATICS ANALYSIS

8.4 DATA VISUALIZATION & ANALYSIS SERVICES

8.4.1 INCREASED DEMAND FOR ADVANCED TOOLS FOR COMPLEX SPATIAL GENOMICS DATA INTERPRETATION TO SUPPORT MARKET GROWTH

9 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY APPLICATION

9.1 INTRODUCTION

9.2 TRANSLATIONAL RESEARCH

9.2.1 CANCER

9.2.1.1 Spatial genomics and transcriptomics to map precise locations of DNA and RNA within tumor tissues in cancer research

9.2.2 IMMUNOLOGY

9.2.2.1 Need for better understanding of immune cell interactions and tissue-specific immune responses to propel segment growth

9.2.3 NEUROSCIENCE

9.2.3.1 Increased focus on mapping cellular diversity for analyzing brain function and dysfunction to aid market growth

9.2.4 INFECTIOUS DISEASES

9.2.4.1 Need for enhanced understanding of pathogen-host interactions at tissue

level to drive adoption

9.2.5 OTHER DISEASES

9.3 DRUG DISCOVERY & DEVELOPMENT

9.3.1 RISING USE OF RNA-SEQ IN DISEASE MANAGEMENT DRUG DISCOVERY TO DRIVE MARKET

10 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,

BY END USER

10.1 INTRODUCTION

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO TRANSFORM DISEASE RESEARCH AND STREAMLINE DRUG TARGET VALIDATION

10.3 ACADEMIC & RESEARCH INSTITUTES

10.3.1 FOCUS ON FOUNDATIONAL DISCOVERIES AND CELLULAR INSIGHTS ABOUT COMPLEX BIOLOGICAL SYSTEMS TO AID MARKET GROWTH

10.4 CROS & CDMOS

10.4.1 GROWING DEMAND FOR PRECISE SPATIAL MOLECULAR INSIGHTS TO PROPEL MARKET GROWTH

10.5 CLINICAL DIAGNOSTIC LABORATORIES

10.5.1 IMPROVED DIAGNOSTIC ACCURACY IN PATHOGEN DETECTION AND GENOMIC ANALYSIS TO AID MARKET GROWTH

11 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY END USER

11.1 INTRODUCTION

11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO OPTIMIZE BIOMARKER DEVELOPMENT AND IMPROVE CLINICAL TRIAL DESIGN

11.3 ACADEMIC & RESEARCH INSTITUTES

11.3.1 NEED FOR TOOLS FOR MAPPING CELLULAR ENVIRONMENTS AND STUDYING DISEASE MECHANISMS TO PROPEL MARKET GROWTH

11.4 OTHER END USERS

12 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY REGION

12.1 INTRODUCTION

12.2 NORTH AMERICA

12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK

12.2.2 US

12.2.2.1 US to dominate North American spatial genomics & transcriptomics market during forecast period

12.2.3 CANADA

12.2.3.1 Favorable government initiatives and high incidence of infectious diseases to support market growth

12.3 EUROPE

12.3.1 EUROPE: MACROECONOMIC OUTLOOK

12.3.2 GERMANY

12.3.2.1 Advanced genomics research and presence of several key companies to spur market growth

12.3.3 UK

12.3.3.1 Increasing government funding and rising demand for new diagnostic biomarkers to aid market growth

12.3.4 FRANCE

12.3.4.1 Increasing investments in life science R&D and rising number of biotech companies to propel market growth

12.3.5 ITALY

12.3.5.1 Increasing focus on neuroscience and rare disease research to augment market growth

12.3.6 SPAIN

12.3.6.1 Focus on advanced cancer research and increased need for personalized medicines to propel market growth

12.3.7 REST OF EUROPE

12.4 ASIA PACIFIC

12.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK

12.4.2 CHINA

12.4.2.1 Increasing R&D spending by government and biopharma companies to propel market growth

12.4.3 JAPAN

12.4.3.1 Favorable government policies and high R&D funding to boost market growth

12.4.4 INDIA

12.4.4.1 Increasing collaborations between hospitals and diagnostics centers to boost market growth

12.4.5 SOUTH KOREA

12.4.5.1 Increased research on advanced precision medicines and well-established biotechnology infrastructure to aid market growth

12.4.6 AUSTRALIA

12.4.6.1 Strategic focus on advancing cancer research and precision oncology to boost market growth

12.4.7 REST OF ASIA PACIFIC

12.5 LATIN AMERICA

12.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK

12.5.2 BRAZIL

12.5.2.1 Increasing adoption of biomarkers for drug discovery & development to drive market

12.5.3 MEXICO

12.5.3.1 Favorable funding scenario in biotechnology sector and high funding in biomanufacturing to augment market growth

12.5.4 REST OF LATIN AMERICA

12.6 MIDDLE EAST

12.6.1 LOWER R&D INVESTMENTS AND WEAK INFRASTRUCTURAL DEVELOPMENTS TO HINDER MARKET GROWTH

12.6.2 MIDDLE EAST: MACROECONOMIC OUTLOOK

12.7 AFRICA

12.7.1 INCREASING FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO SUPPORT GROWTH OF BIOTECHNOLOGY INDUSTRY

12.7.2 AFRICA: MACROECONOMIC OUTLOOK

13 COMPETITIVE LANDSCAPE

13.1 INTRODUCTION

13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET

13.3 REVENUE ANALYSIS, 2019-2023

13.4 MARKET SHARE ANALYSIS, 2023

13.4.1 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET

13.4.2 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET

13.4.3 RANKING OF KEY MARKET PLAYERS

13.5 COMPANY VALUATION & FINANCIAL METRICS

13.5.1 COMPANY VALUATION

13.5.2 FINANCIAL METRICS

13.6 BRAND/PRODUCT COMPARISON

13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

13.7.1 STARS

- 13.7.2 EMERGING LEADERS
- 13.7.3 PERVASIVE PLAYERS
- 13.7.4 PARTICIPANTS
- 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
 - 13.7.5.1 Company footprint
 - 13.7.5.2 Region footprint
 - 13.7.5.3 Offering footprint
 - 13.7.5.4 Technique footprint
 - 13.7.5.5 Application footprint

- 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
 - 13.8.1 PROGRESSIVE COMPANIES
 - 13.8.2 RESPONSIVE COMPANIES
 - 13.8.3 DYNAMIC COMPANIES
 - 13.8.4 STARTING BLOCKS
 - 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
 - 13.8.5.1 Detailed list of key startups/SMEs
 - 13.8.5.2 Competitive benchmarking of key startups/SMEs
- 13.9 COMPETITIVE SCENARIO
 - 13.9.1 PRODUCT LAUNCHES
 - 13.9.2 DEALS
 - 13.9.3 EXPANSIONS

14 COMPANY PROFILES

- 14.1 KEY PLAYERS
 - 14.1.1 10X GENOMICS
 - 14.1.1.1 Business overview
 - 14.1.1.2 Products/Services/Solutions offered
 - 14.1.1.3 Recent developments
 - 14.1.1.3.1 Product launches
 - 14.1.1.3.2 Deals
 - 14.1.1.3.3 Expansions
 - 14.1.1.4 MnM view
 - 14.1.1.4.1 Key strengths
 - 14.1.1.4.2 Strategic choices
 - 14.1.1.4.3 Weaknesses and competitive threats
 - 14.1.2 BIO-TECHNE
 - 14.1.2.1 Business overview
 - 14.1.2.2 Products/Services/Solutions offered

- 14.1.2.3 Recent developments
 - 14.1.2.3.1 Product launches
 - 14.1.2.3.2 Deals
 - 14.1.2.3.3 Expansions
- 14.1.2.4 MnM view
 - 14.1.2.4.1 Key strengths
 - 14.1.2.4.2 Strategic choices
 - 14.1.2.4.3 Weaknesses and competitive threats
- 14.1.3 NANOSTRING TECHNOLOGIES, INC. (BRUKER SPATIAL BIOLOGY, INC.)
 - 14.1.3.1 Business overview
 - 14.1.3.2 Products/Services/Solutions offered
 - 14.1.3.3 Recent developments
 - 14.1.3.3.1 Product launches
 - 14.1.3.3.2 Deals
 - 14.1.3.4 MnM view
 - 14.1.3.4.1 Key strengths
 - 14.1.3.4.2 Strategic choices
 - 14.1.3.4.3 Weaknesses and competitive threats
- 14.1.4 STANDARD BIOTOOLS
 - 14.1.4.1 Business overview
 - 14.1.4.2 Products/Services/Solutions offered
 - 14.1.4.3 Recent developments
 - 14.1.4.3.1 Product launches
 - 14.1.4.3.2 Deals
 - 14.1.4.4 MnM view
 - 14.1.4.4.1 Key strengths
 - 14.1.4.4.2 Strategic choices
 - 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 ILLUMINA, INC.
 - 14.1.5.1 Business overview
 - 14.1.5.2 Products/Services/Solutions offered
 - 14.1.5.3 Recent developments
 - 14.1.5.3.1 Product launches
 - 14.1.5.3.2 Deals
 - 14.1.5.4 MnM view
 - 14.1.5.4.1 Key strengths
 - 14.1.5.4.2 Strategic choices
 - 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 BIO-RAD LABORATORIES, INC.

- 14.1.6.1 Business overview
- 14.1.6.2 Products/Services/Solutions offered
- 14.1.6.3 Recent developments
 - 14.1.6.3.1 Product launches
 - 14.1.6.3.2 Deals
- 14.1.7 AKOYA BIOSCIENCES, INC.
 - 14.1.7.1 Business overview
 - 14.1.7.2 Products/Services/Solutions offered
 - 14.1.7.3 Recent developments
 - 14.1.7.3.1 Product launches
 - 14.1.7.3.2 Deals
 - 14.1.7.3.3 Expansions
- 14.1.8 VISIOPHARM A/S
 - 14.1.8.1 Business overview
 - 14.1.8.2 Products/Services/Solutions offered
 - 14.1.8.3 Recent developments
 - 14.1.8.3.1 Product launches
 - 14.1.8.3.2 Deals
- 14.1.9 DANAHER CORPORATION
 - 14.1.9.1 Business overview
 - 14.1.9.2 Products/Services/Solutions offered
 - 14.1.9.3 Recent developments
 - 14.1.9.3.1 Deals
- 14.1.10 SEVEN BRIDGES GENOMICS
 - 14.1.10.1 Business overview
 - 14.1.10.2 Products/Services/Solutions offered
 - 14.1.10.3 Recent developments
 - 14.1.10.3.1 Deals
- 14.1.11 REVVITY
 - 14.1.11.1 Business overview
 - 14.1.11.2 Products/Services/Solutions offered
 - 14.1.11.3 Recent developments
 - 14.1.11.3.1 Product launches & approvals
 - 14.1.11.3.2 Deals
- 14.1.12 VIZGEN INC.
 - 14.1.12.1 Business overview
 - 14.1.12.2 Products/Services/Solutions offered
 - 14.1.12.3 Recent developments
 - 14.1.12.3.1 Product launches

- 14.1.12.3.2 Deals
- 14.1.13 VERACYTE, INC.
 - 14.1.13.1 Business overview
 - 14.1.13.2 Products/Services/Solutions offered
- 14.1.14 NATERA, INC.
 - 14.1.14.1 Business overview
 - 14.1.14.2 Products/Services/Solutions offered
 - 14.1.14.3 Recent developments
 - 14.1.14.3.1 Product launches
 - 14.1.14.3.2 Expansions
- 14.1.15 MACROGEN INC.
 - 14.1.15.1 Business overview
 - 14.1.15.2 Products/Services/Solutions offered
 - 14.1.15.3 Recent developments
 - 14.1.15.3.1 Deals
- 14.1.16 MILTENYI BIOTEC
 - 14.1.16.1 Business overview
 - 14.1.16.2 Products/Services/Solutions offered
 - 14.1.16.3 Recent developments
 - 14.1.16.3.1 Deals
- 14.2 OTHER PLAYERS
 - 14.2.1 BIOMARKER TECHNOLOGIES (BMKGENE)
 - 14.2.2 ULTIVUE, INC.
 - 14.2.3 RARECYTE, INC.
 - 14.2.4 S2 GENOMICS, INC.
 - 14.2.5 ADMERA HEALTH
 - 14.2.6 SONY BIOTECHNOLOGY INC.
 - 14.2.7 CANTATA BIO
 - 14.2.8 NUCLEAI, INC.
 - 14.2.9 VISIKOL, INC.
 - 14.2.10 IONPATH, INC.
 - 14.2.11 BIOSPYDER, INC.
 - 14.2.12 SINGULAR GENOMICS SYSTEMS, INC.
 - 14.2.13 LUNAPHORE TECHNOLOGIES SA
 - 14.2.14 REBUS BIOSYSTEMS, INC.

15 APPENDIX

15.1 DISCUSSION GUIDE

- 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 15.3 CUSTOMIZATION OPTIONS
- 15.4 RELATED REPORTS
- 15.5 AUTHOR DETAILS

I would like to order

Product name: Spatial Genomics & Transcriptomics Market by Product (Instruments, Consumables, Services), Technique (Transcriptomics (IHC, ISH), Genomics (LCM), Service Type (Sample Prep, Sequencing), Application (Translation Research (Cancer)) - Global Forecast to 2029

Product link: <https://marketpublishers.com/r/SE6D93297642EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SE6D93297642EN.html>